This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
The PTC Therapeutics oral, brain-penetrant tubulin-binding agent, PTC596, is in Ph. I clinical studies for advanced solid tumors (starting dose of…
molecule
2 years ago ●
1 min read
The Janssen gut-restricted COX-2 inhibitor, compound 10, is a tool compound used to test the hypothesis that gut-restricted COX-2 inhibition would…
molecule
2 years ago ●
1 min read
The GSK BET BD2 inhibitor, GSK852, is one of a series of BD2-targeting compounds published last month by GSK (see a…
molecule
2 years ago ●
1 min read
The BMS AAK1 kinase inhibitor, compound 59, is brain-penetrant and acts on the CNS. The target was identified from a phenotypic…
molecule
2 years ago ●
1 min read
The Genentech PI3Kα isoform-selective kinase inhibitor and mutant PI3Kα degrader GDC-0077 (inavolisib) selectively depletes the oncogenic mutant p110α catalytic subunit of PI3Kα…
molecule
2 years ago ●
2 mins read
The Hanmi/Genentech type II RAF kinase inhibitor, belvarafenib, is a potent and selective inhibitor of RAF dimers. GNE-9815 was covered last month,…
molecule
2 years ago ●
2 mins read
Load More
